Tscan Therapeutics
Price & Volume
Stats
See moreOpen | $0.98 |
Previous Close | $0.98 |
Day Range | $0.98-$1.02 |
52W Range | $0.88-$2.57 |
Market Cap | $58.4M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $8.4M |
Revenue Growth (YoY) | 139.4% |
Gross Profit (12 Mos) | -$12.5M |
Diluted EPS | -$1.12 |
News
See moreYahoo Finance • 2 months ago
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Yahoo Finance • 2 months ago
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
Yahoo Finance • 3 months ago
TScan Therapeutics GAAP EPS of -$0.28, revenue of $2.51M
About
CEO | Dr. Gavin MacBeath Ph.D. |
CFO | Mr. Jason A. Amello CPA |
Address | 830 Winter Street, Waltham, MA, United States, 02451 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 146 |
